A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer (Q57975564)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer	article

Statements

scholarly article

0 references

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

fallopian tube cancer

1 reference

based on heuristic

inferred from title

fallopian tube carcinoma

1 reference

based on heuristic

inferred from title

object named as

Jason Konner

1

0 references

Carol Aghajanian

9

object named as

Carol A. Aghajanian

0 references

author name string

Russell J. Schilder

2

0 references

Felicia A. DeRosa

3

0 references

Scott R. Gerst

4

0 references

William P. Tew

5

0 references

Paul J. Sabbatini

6

0 references

Martee L. Hensley

7

0 references

David R. Spriggs

8

0 references

language of work or name

0 references

publication date

August 2008

0 references

Gynecologic Oncology

0 references

110

0 references

140-145

0 references

2

0 references

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Growth factors in development, transformation, and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Role of an anti-epidermal growth factor receptor in treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.018

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.04.018

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57975564&oldid=2047140219"